Nav: Home

Heparin derived from cattle is equivalent to heparin from pigs, study finds

October 05, 2016

MAYWOOD, IL - As demand for the widely used blood thinning drug heparin continues to grow, experts worry of possible shortages of the essential medication.

Heparin is primarily derived from pigs, and to reduce the risk of shortages, cattle have been proposed as an additional source. A new study co-authored by Loyola University Chicago Stritch School of Medicine researchers has found that heparin derived from cattle (known as bovine heparin) has equivalent anti-clotting properties to heparin derived from pigs (porcine heparin).

The study found minor differences in the structural and molecular characteristics of bovine and porcine heparin, but these differences did not significantly affect the drug's anticoagulant properties.

The study co-authored by Jawed Fareed, PhD, and colleagues is published in the journal Clinical and Applied Thrombosis/Hemostasis. Fareed is a professor in the Department of Molecular Pharmacology and Therapeutics and Department of Pathology and director of the Hemostasis and Thrombosis Research Program at Loyola University Chicago Stritch School of Medicine.

Fareed is one of the world's leading heparin scientists. He has researched heparin for 40 years and is the author or co-author of more than 200 scientific papers on heparin.

The study is titled "Analysis of Heparins Derived from Bovine Tissues and Comparison to Porcine Intestinal Heparins." Other Loyola co-authors are Debra Hoppensteadt, PhD and Walter Jeske, PhD. Nine other co-authors, including corresponding author Robert J. Linhardt, PhD, are with the Rensselaer Polytechnic Institute.

Heparin is an anticoagulant (blood thinner), and one of the world's most commonly used drugs. Heparin is used to prevent or treat blood clots in veins, arteries and lungs and used before surgery to reduce the risks of clots. Heparin is injected or administered intravenously.

Heparin also is used in devices that come in contact with blood, such as kidney dialysis machines and test tubes.

Heparin used in the U.S. now comes from the intestines of pigs that are slaughtered for meat. (The heparin is derived from what would otherwise be a waste product.) Seventy-five percent of the heparin used in the U.S. comes from China, which is the world's largest pork producer.

"Because heparin is a widely used essential drug with no medical alternatives in certain clinical situations, the U.S. healthcare system could be vulnerable to fluctuations in the crude heparin supply," according to the Food and Drug Administration's Center for Drug Evaluation and Research. The center is evaluating the possible reintroduction of bovine heparin in order to address possible shortages or contamination of the global porcine heparin supply.

Bovine heparin could be derived from the intestines and lungs of cattle that are slaughtered for meat. Because cows are larger than pigs, one cow can produce much more heparin than one pig.

Bovine heparin was voluntarily withdrawn from the market during the 1980s due to worries that it could, in rare cases, cause thrombocytopenia (shortage of platelets leading to bleeding and bruising) or be contaminated with bovine spongiform encephalopathy (mad cow disease). Those fears have been put to rest by advancements in manufacturing and quality control that have resulted in purer forms of heparin, Fareed said.

Some experts remain skeptical about bovine heparin because it has a different chemical structure than porcine heparin. To examine this question, Fareed and colleagues compared individually manufactured batches of bovine heparin with individually manufactured batches of porcine heparin. The anticoagulant activities of the two groups were found to be equivalent.
-end-
The study was supported by grants from the National Institutes of Health and National Science Foundation.

Loyola University Health System

Related Heparin Articles:

URI chemistry professor develops contaminant detection technique for heparin
In 2008, a contaminant eluded the quality safeguards in the pharmaceutical industry and infiltrated a large portion of the supply of the popular blood thinner heparin, sickening hundreds and killing about 100 in the US.
Synthetic version of popular anticoagulant poised for clinical trials
A synthetic version of low molecular weight heparin is poised for clinical trials and development as a drug for patients with clotting disorders, and those undergoing procedures such as kidney dialysis, heart bypass surgery, stent implantation, and knee and hip replacement.
Heparin stimulates food intake and body weight gain in mice
Research shows that heparin, which is well known for its role as an anticoagulant, can also promote food intake and body weight increase in animal models.
Apixaban lowers stroke risk in AF patients undergoing cardioversion (EMANATE)
Apixaban lowers the risk of stroke compared to warfarin in anticoagulation-naïve patients with atrial fibrillation scheduled for elective cardioversion, according to late-breaking results from the EMANATE trial presented today in a Hot Line LBCT Session at ESC Congress.
No difference in rate of adverse cardiovascular events when comparing anticoagulants
In patients undergoing transradial primary percutaneous coronary intervention (PCI) for ST elevation myocardial infarction (STEMI), there was no significant difference in the rate of a composite of death, myocardial infarction and stroke whether they were anticoagulated with bivalirudin or unfractioned heparin, according to a study today in JACC: Cardiovascular Interventions.
More Heparin News and Heparin Current Events

Best Science Podcasts 2019

We have hand picked the best science podcasts for 2019. Sit back and enjoy new science podcasts updated daily from your favorite science news services and scientists.
Now Playing: TED Radio Hour

Erasing The Stigma
Many of us either cope with mental illness or know someone who does. But we still have a hard time talking about it. This hour, TED speakers explore ways to push past — and even erase — the stigma. Guests include musician and comedian Jordan Raskopoulos, neuroscientist and psychiatrist Thomas Insel, psychiatrist Dixon Chibanda, anxiety and depression researcher Olivia Remes, and entrepreneur Sangu Delle.
Now Playing: Science for the People

#537 Science Journalism, Hold the Hype
Everyone's seen a piece of science getting over-exaggerated in the media. Most people would be quick to blame journalists and big media for getting in wrong. In many cases, you'd be right. But there's other sources of hype in science journalism. and one of them can be found in the humble, and little-known press release. We're talking with Chris Chambers about doing science about science journalism, and where the hype creeps in. Related links: The association between exaggeration in health related science news and academic press releases: retrospective observational study Claims of causality in health news: a randomised trial This...